This was the stock's second consecutive day of losses.

San Francisco observed World AIDS Day with a public program at the National AIDS Memorial Grove in Golden Gate Park.

Since 2010, less than 10% of the time the market traded at a 5% premium or more. With the market trading well above the fair ...

Gilead Sciences, Inc. (GILD) stock saw a decline, ending the day at $92.49 which represents a decrease of $-1.53 or -1.63% from the prior close of $94.02. The stock opened at $93.81 and touched a low ...

Pacira BioSciences PCRX announced the reception of the ‘940 patent from the U.S. Patent and Trademark Office that protects ...

In the past 60 days, Gilead Sciences’ earnings estimates have risen from $3.79 to $4.32 per share for 2024, while that for ...

Enhertu won its initial China nod in early 2023 as a treatment for previously treated HER2-positive breast cancer and later ...

Catch up on all the biggest pharma news to hit the industry last month, with stories spanning the US election, new ...

GILD and Germany-based Tubulis collaborate to discover and develop an antibody-drug conjugate against a solid tumor target.

Timely remdesivir treatment in immunocompromised patients infected with COVID-19 is associated with improved survival outcomes.

Scancell has a pipeline of five anti-glycan antibodies, with SC129 accompanied by fucosyl GM1-targeting SC134 for small cell ...

Novartis, Gilead, Roche and Takeda commit to new partners in a spate of mid-sized collaborations this week. Meanwhile, ...